Prominent publications by John M Lachin

KOL Index score: 21400

BACKGROUND: Empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced cardiovascular morbidity and mortality in patients with type 2 diabetes mellitus and established cardiovascular disease in the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients). Urinary glucose excretion with empagliflozin decreases with declining renal function, resulting in less potency for glucose lowering in patients with kidney disease. We ...

Known for Cardiovascular Disease |  Diabetes Mellitus |  Type 2 |  Chronic Kidney |  Patients Egfr
KOL Index score: 17055

BACKGROUND: An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population.

METHODS: In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy ...

Known for Diabetes Therapy |  Filtration Rate |  Type 1 |  Estimated Gfr |  Edic Study
KOL Index score: 17031

BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.

METHODS: We evaluated rosiglitazone, metformin, and glyburide as initial treatment for recently diagnosed type 2 diabetes in a double-blind, randomized, controlled clinical trial involving 4360 patients. The patients were treated for a median of 4.0 years. The primary outcome was the time to monotherapy ...

Known for Rosiglitazone Metformin |  Glycemic Durability |  Monotherapy Failure |  Plasma Glucose |  Ldl Diabetes Mellitus
KOL Index score: 16269

AIMS: We previously reported that in the EMPA-REG OUTCOME(®) trial, empagliflozin added to standard of care reduced the risk of 3-point major adverse cardiovascular events, cardiovascular and all-cause death, and hospitalization for heart failure in patients with type 2 diabetes and high cardiovascular risk. We have now further investigated heart failure outcomes in all patients and in subgroups, including patients with or without baseline heart failure.


Known for Heart Failure |  Empagliflozin Patients |  Cardiovascular Risk |  Type 2 Diabetes |  Reg Outcome
KOL Index score: 15762

BACKGROUND: Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium-glucose cotransporter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular events. We wanted to determine the long-term renal effects of empagliflozin, an analysis that was a prespecified component of the secondary microvascular outcome of that trial.


Known for Type 2 Diabetes |  Kidney Disease |  Empagliflozin Patients |  Nephropathy Progression |  Renal Events
KOL Index score: 15724

OBJECTIVE: This study investigated the long-term effects of intensive diabetic treatment on the progression of atherosclerosis, measured as common carotid artery intima-media thickness (IMT).

RESEARCH DESIGN AND METHODS: A total of 1,116 participants (52% men) in the Epidemiology of Diabetes Interventions and Complications (EDIC) trial, a long-term follow-up of the Diabetes Control and Complications Trial (DCCT), had carotid IMT measurements at EDIC years 1, 6, and 12. Mean age was 46 ...

Known for Complications Trial |  Carotid Artery |  Imt Progression |  Diabetes Control |  12 Years
KOL Index score: 15333

IMPORTANCE: Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might increase heart failure (HF) risk in type 2 diabetes mellitus (T2DM). The DPP4i sitagliptin has been shown to be noninferior to placebo with regard to primary and secondary composite atherosclerotic cardiovascular (CV) outcomes in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS).

OBJECTIVE: To assess the association of sitagliptin use with hospitalization for HF ...

Known for Secondary Analysis |  Hhf Death |  Sitagliptin Placebo |  Heart Failure |  Diabetes Mellitus
KOL Index score: 15286

The relationships between long-term intensive control of glycemia and indicators of skin collagen glycation (furosine), glycoxidation (pentosidine and N(epsilon)-[carboxymethyl]-lysine [CML]), and crosslinking (acid and pepsin solubility) were examined in 216 patients with type 1 diabetes from the primary prevention and secondary intervention cohorts of the Diabetes Control and Complications Trial. By comparison with conventional treatment, 5 years of intensive treatment was associated ...

Known for Glycated Collagen |  Complications Trial |  Diabetes Control |  Conventional Therapy |  Intensive Treatment
KOL Index score: 14962

BACKGROUND: Cardiovascular disease causes severe morbidity and mortality in type 1 diabetes, although the specific risk factors and whether chronic hyperglycemia has a role are unknown. We examined the progression of carotid intima-media thickness, a measure of atherosclerosis, in a population with type 1 diabetes.

METHODS: As part of the Epidemiology of Diabetes Interventions and Complications (EDIC) study, the long-term follow-up of the Diabetes Control and Complications Trial (DCCT), ...

Known for Carotid Intima |  Media Thickness |  Intensive Diabetes |  Type 1 |  Risk Factors Progression
KOL Index score: 14799

BACKGROUND: Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load, overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes.

METHODS: We randomly assigned 3234 nondiabetic ...

Known for Lifestyle Intervention |  Placebo Metformin |  Type 2 |  Incidence Diabetes |  Elevated Fasting
KOL Index score: 14723

The Epidemiology of Diabetes Interventions and Complications (EDIC) study, an observational follow-up of the Diabetes Control and Complications Trial (DCCT) type 1 diabetes cohort, measured coronary artery calcification (CAC), an index of atherosclerosis, with computed tomography (CT) in 1,205 EDIC patients at approximately 7-9 years after the end of the DCCT. We examined the influence of the 6.5 years of prior conventional versus intensive diabetes treatment during the DCCT, as well as ...

Known for Diabetes Interventions |  Coronary Artery Calcification |  1 Diabetic |  Cac Dcct |  Edic Study
KOL Index score: 14682

OBJECTIVE: High cholesterol levels in circulating immune complexes (IC), surrogate markers of modified LDL, are associated with increased carotid intima-media thickness (IMT) and cardiovascular events in type 1 diabetes. Different modifications of LDL are involved in IC formation, but which of these are predictive of vascular events is not known. Therefore, we measured oxidized LDL (oxLDL), advanced glycation end products-modified LDL (AGE-LDL), and malondialdehyde-modified LDL (MDA-LDL) ...

Known for Modified Ldl |  Advanced Glycation |  Type 1 Diabetes |  Circulating Immune Complexes |  Carotid Intima
KOL Index score: 14097

BACKGROUND: The effects of empagliflozin, an inhibitor of sodium-glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.

METHODS: We randomly assigned patients to receive 10 mg or 25 mg of empagliflozin or placebo once daily. The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled ...

Known for Type 2 Diabetes |  Cardiovascular Outcome |  Patients Empagliflozin |  Placebo Lower Rate |  Nonfatal Stroke
KOL Index score: 13903

BACKGROUND: Intensive diabetes therapy aimed at achieving near normoglycemia reduces the risk of microvascular and neurologic complications of type 1 diabetes. We studied whether the use of intensive therapy as compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the long-term incidence of cardiovascular disease.

METHODS: The DCCT randomly assigned 1441 patients with type 1 diabetes to intensive or conventional therapy, treating them for ...

Known for Cardiovascular Disease |  Diabetes Treatment |  Conventional Therapy Dcct |  Intensive Therapy |  Stroke Death
KOL Index score: 13873

BACKGROUND: Microalbuminuria is a common diagnosis in the clinical care of patients with type 1 diabetes mellitus. Long-term outcomes after the development of microalbuminuria are variable.

METHODS: We quantified the incidence of and risk factors for long-term renal outcomes after the development of microalbuminuria in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The DCCT randomly assigned 1441 persons with type ...

Known for Diabetes Control |  Renal Outcomes |  Type 1 |  Development Microalbuminuria |  Progression Macroalbuminuria


John M Lachin: Influence Statistics

Sample of concepts for which John M Lachin is among the top experts in the world.
Concept World rank
sif ventricular mass #1
mets 341 #1
statistical probability theory #1
maximin efficient test #1
lower egfr pinp #1
sided test #1
gfr followup data #1
multiply matched case #1
cardiovascular death presence #1
feedings birth #1
type topic rituximab #1
diabetes sorcs1 #1
repeated measures time #1
miettinen schlesselman #1
distribution observed values #1
prior dcct therapy #1
humans diabetes control #1
21 p002 increase #1
endorgan diabetic complications #1
adjustment a1c level #1
rituximab auc #1
microalbuminuria sustained microalbuminuria #1
robust data cpeptide #1
cac score glucosepane #1
clinically beneficial outcomes #1
cdc 1 2 #1
dcct 18 years #1
hhf loguacr #1
agreement ecgderived #1
studies new agents #1
18yr period #1
complete 10age panel #1
adjustment a1c #1
dcct edic mets #1
3step progression #1
age goal achievement #1
duration t1d #1
outcome coefficient #1
dissolution fixed dose #1
participant conventional therapy #1
egfr remission #1
analyses logx1 #1
progression microvascular #1
tertile updated hba1c #1
standard therapy plasmapheresis #1
death diabetes empagliflozin #1
incident albuminuria incident #1
clinical trials foreword #1
multivariate analysis furosine #1
initial goals goals #1

Key People For Type 1 Diabetes

Top KOLs in the world
John M Lachin
type 1 diabetes cardiovascular disease complications trial
David Matthew Nathan
type 2 diabetes insulin resistance cardiovascular disease
William V Tamborlane
type 1 diabetes young children growth hormone
Patricia A Cleary
type 1 diabetes optic neuritis intensive therapy
George S Eisenbarth
type 1 diabetes nod mice celiac disease
Marian J Rewers
type 1 diabetes islet autoimmunity celiac disease

John M Lachin:Expert Impact

Concepts for whichJohn M Lachinhas direct influence:Type 1 diabetes,  1 diabetes,  Type 1,  Type 2 diabetes,  Cardiovascular disease,  Diabetes interventions,  Diabetes mellitus,  Diabetes control.

John M Lachin:KOL impact

Concepts related to the work of other authors for whichfor which John M Lachin has influence:Type 2 diabetes,  Weight loss,  Heart failure,  Glycemic control,  Diabetic retinopathy,  Metabolic syndrome,  Insulin resistance.



Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

The Biostatistics Center, George Washington University, Rockville, MD, USA | The Biostatistics Center, Milken Institute School of Public Health, The George Washington University, Washington, DC. | Biostatistics Center, George Washington University, R

FREE Custom List